Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cost of Revenue	41.76	41.76	26.45	42.33	38.96	26.34
Gross Profit	-41.76	-41.76	-26.45	-42.33	-38.96	-26.34
Selling, General & Admin	38.65	29.94	26.67	20.74	12.77	9.97
Operating Expenses	34.68	29.94	26.67	20.74	12.77	9.97
Operating Income	-76.44	-71.7	-53.13	-63.07	-51.73	-36.31
Interest Expense	-0.26	-3.16	-2.53	-1.49	-0.94	-1.76
Interest & Investment Income	0.94	0.91	0.97	-	-	-
Earnings From Equity Investments	-0.14	-0.1	-0.01	-0.05	-0.05	-
Other Non Operating Income (Expenses)	1.39	1.15	0.05	0.47	-0.45	1.98
EBT Excluding Unusual Items	-74.52	-72.91	-54.65	-64.14	-53.16	-36.09
Asset Writedown	-	-	-	-	-	-0.53
Other Unusual Items	95.64	-2.46	-4.33	-1.91	-	-1.9
Pretax Income	21.12	-75.36	-58.98	-66.05	-53.16	-38.51
Income Tax Expense	0	0	0	0	0	-3.27
Earnings From Continuing Operations	21.12	-75.37	-58.98	-66.05	-53.16	-35.24
Net Income	21.12	-75.37	-58.98	-66.05	-53.16	-35.24
Preferred Dividends & Other Adjustments	-	-	-	-	-	13.63
Net Income to Common	21.12	-75.37	-58.98	-66.05	-53.16	-48.87
Shares Outstanding (Basic)	25	19	13	11	8	4
Shares Outstanding (Diluted)	25	19	13	11	8	4
Shares Change (YoY)	91.92%	48.29%	17.96%	38.91%	110.43%	298.84%
EPS (Basic)	0.83	-4.06	-4.72	-6.23	-6.96	-13.47
EPS (Diluted)	0.83	-4.06	-4.72	-6.23	-6.96	-13.47
Free Cash Flow	-64.05	-68.79	-42.97	-56.67	-54.25	-31.79
Free Cash Flow Per Share	-2.51	-3.71	-3.44	-5.34	-7.11	-8.76
EBITDA	-76.32	-71.59	-53.08	-62.87	-51.46	-35.76
D&A For EBITDA	0.12	0.11	0.04	0.2	0.26	0.55
EBIT	-76.44	-71.7	-53.13	-63.07	-51.73	-36.31

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q